GRI Bio announces 1-for-28 reverse stock split effective Jan 23, 2026 to regain Nasdaq compliance

GRI Bio, Inc.

Stockholders approved reverse split at January 15, 2026 special meeting.
Outstanding shares to reduce from ~15,016,434 to ~536,301; authorized shares unchanged.
Cash in lieu of fractional shares at closing price on Jan 23, 2026.
Proportional adjustments to options, warrants, convertible securities and stock plans.
Trading to begin on split-adjusted basis on Nasdaq under ticker 'GRI' on Jan 26, 2026.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

GRI Bio, Inc.: Filed Certificate of Amendment to effect a 1-for-28 reverse stock split of common stock, effective January 23, 2026 (effective 2026-01-23).

Change: charter amendment
Effective: 2026-01-23

Exact text from the filing

On January 21, 2026, GRI Bio, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its amended and restated certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-28 (the “Reverse Stock Split”).

View on SEC.gov

Browse all governance changes →

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-26-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.